---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic impact on families"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic impact on families. Topics: Caregiver attendance, missed work, and travel for intravesical therapy; Financial toxicity after radical cystectomy versus bladder-sparing therapy; Financial toxicity among patients with NMIBC in a diverse urban population; Financial toxicity in bladder cancer: definition and associated factors; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of BCG-unresponsive high-risk non-muscle-invasive bladder cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver attendance, missed work, and travel for intravesical therapy

> “A travel time of >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of respondents. Fifty-six percent (128/232) brought caregivers to their appointments, and 36% (82/230) missed work to receive treatment.”
> “Bladder cancer patients reported considerable travel distances, time requirements, and need for caregiver support when receiving intravesical therapy.”

Source: [Myers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993341/)

<a id="topic-2.2.1.8.3-2"></a>

### Financial toxicity after radical cystectomy versus bladder-sparing therapy

> “Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST),”
> “which includes questions about concern with covering the costs of treatment, out-of-pocket expenses, ability to work, and impact and worry about finances. COST scores range from 0 to 44, with lower scores indicating greater financial distress.”
> “Participants in the BST arm reported significantly higher financial toxicity and financial difficulties 12 months after enrollment than participants in the RC arm.”
> “Participants in the BST and RC arms endorsed similar financial burden at enrollment. However, by 12 months, participants in the RC arm experienced lower financial difficulties and lower financial toxicity. Although RC is a morbid surgery with a high initial burden, after recovery, those patients mostly experience low health care utilization. Conversely, patients undergoing BST have several induction and maintenance treatments in the year after their recurrence coupled with quarterly surveillance cystoscopies. The financial burden of BST may increase going forward, given recent US Food and Drug Administration approvals of nadofaragene and nogapendekin for BCG-unresponsive NMIBC, which are substantially more expensive than currently available BSTs.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.1.8.3-3"></a>

### Financial toxicity among patients with NMIBC in a diverse urban population

> “Hundred patients with NMIBC were surveyed. The median age was 74 years (IQR, 66-79).”
> “The median COST score was 23 (IQR,15-33). 61% of patients reported at least mild FT (COST score 25-14). A total of 21% reported moderate FT (COST score < 14). Black patients were more likely to experience FT than Caucasians (73% vs 37%, P < .05).”
> “Overall median household income was $30,000 (IQR, $18,250-$60,750), and increasing income had a significant positive correlation with COST score (Spearman ρ = 0.502, P < .001).”

Source: [Nadelmann et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42143549/)

<a id="topic-2.2.1.8.3-4"></a>

### Financial toxicity in bladder cancer: definition and associated factors

> “Financial toxicity (FT) refers to the detrimental effects of financial strain caused by a cancer diagnosis on the well-being of patients and their families.”
> “Of 629 titles identified, 19, ten, and two studies met the inclusion criteria for prostate, bladder, and kidney cancer, respectively, and were included (24 unique articles).”
> “Factors commonly associated with FT included younger age at diagnosis, black race, low socioeconomic status, low education attainment, and rurality. FT was commonly associated with lower quality of life and nonadherence.”

Source: [Bhanvadia et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33820747/)

<a id="topic-2.2.1.8.3-5"></a>

### Indirect costs: lost productivity, retirement, and unemployment

> “Lost productivity for example, contributed to 44% of total cancer care costs in a study of Italian BC patients, and 67% of costs in a recent Iranian study [11-12]. Additionally, this effect may be permanent for many as bladder cancer patients face a roughly 60% retirement rate following diagnosis and 22% unemployment rate for previously full-time workers [13].”
> “Those who are younger, without a college degree, and are black all experience worse financial toxicity [15].”

Source: [Kurnot and Kaye (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11560494/)

<a id="topic-2.2.1.8.3-6"></a>

### Caregiver financial strain after radical cystectomy with urinary diversion

> “Financial strains, including medical costs and potential work interruptions, further complicate their role.”
> “Financial worries were also evident, as a study involving 123 caregivers, 17% of whom were attending to bladder cancer patients with urostomy, revealed heightened economic concerns. The findings suggested pronounced financial strain among caregivers with young children (34%) and those who were older (mean age=56.10 years; SD=10.56).”

Source: [Zhang and Qi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11317044/)

<a id="topic-2.2.1.8.3-7"></a>

### Financial toxicity across bladder cancer stages: systematic review

> “FT is particularly prevalent among younger, less educated, and minority populations.”

Source: [Scilipoti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39730299/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
